Session 2: Automation for Synthetic Biology
My Session Status
Sub Sessions
The incomplete understanding of the relationship between phenotype and cancer genotype limits the efficacy of genome-based cancer therapeutic matching. This gap can be bridged by functional testing of live patient tumor tissues, which holds immense potential to increase the predictive power of current stratification biomarkers and reduce the dismal >90% failure rate of oncology clinical trials. MISO Chip, a Montreal-based startup, offers a groundbreaking solution by leveraging 3D tumor ...
Protein-based materials can be genetically customized for a range of applications. In addition to displaying biocompatibility, tunable bioactivity and responsiveness, they represent sustainable alternatives to conventional synthetic polymers. In particular, proteins that self-assemble into higher order structures and can be produced at large scale are of interest for deployment into wearable devices and alternatives for commodity materials like plastics, textiles and electronic...
The Concordia Genome Foundry is a biofoundry—a specialized laboratory custom-built with automation and analytics infrastructure to achieve high-throughput prototyping and testing of biological systems. The Foundry engages with researchers in academia and industry, in collaborative or service-based agreements, with the aim of accelerating innovation in synthetic biology and biomanufacturing. In so doing, it strives to be a driver of growth in the Canadian and global bioeconomies. Here we pr...